<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E594C221-4738-4152-9CFD-57F6EB31C620"><gtr:id>E594C221-4738-4152-9CFD-57F6EB31C620</gtr:id><gtr:name>Fraunhofer Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AAA90310-B621-460B-B530-35ADEE45DB78"><gtr:id>AAA90310-B621-460B-B530-35ADEE45DB78</gtr:id><gtr:name>C.H. Boehringer Sohn AG &amp; Ko. KG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/ACC57BAC-A62B-4F30-9904-D2A0D0DAC429"><gtr:id>ACC57BAC-A62B-4F30-9904-D2A0D0DAC429</gtr:id><gtr:name>Shino-Test Corporation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9E00513E-B552-46CE-A64C-C0A5AB380DB0"><gtr:id>9E00513E-B552-46CE-A64C-C0A5AB380DB0</gtr:id><gtr:name>Jagiellonian University</gtr:name><gtr:address><gtr:line1>Golebia 24</gtr:line1><gtr:line4>Krakow</gtr:line4><gtr:line5>PL-31-007</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Poland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C9E7988F-9A77-4D99-9554-A038C31D4C21"><gtr:id>C9E7988F-9A77-4D99-9554-A038C31D4C21</gtr:id><gtr:name>University of Catania</gtr:name><gtr:address><gtr:line1>Viale A Doria 6</gtr:line1><gtr:line2>I-95125</gtr:line2><gtr:line4>Catania</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78CA1442-F154-40E7-964B-12FE667ADBE0"><gtr:id>78CA1442-F154-40E7-964B-12FE667ADBE0</gtr:id><gtr:name>Hvidovre Hospital</gtr:name><gtr:address><gtr:line1>Hvidovre Hospital</gtr:line1><gtr:line2>Kettegard Alle 30</gtr:line2><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:line4>Ghent</gtr:line4><gtr:line5>B-9000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1A0DAB7-FD0B-415C-A58B-F4CFC655E3FC"><gtr:id>D1A0DAB7-FD0B-415C-A58B-F4CFC655E3FC</gtr:id><gtr:name>Academic Medical Center (AMC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/41748D4D-016A-42D7-9632-C3261757779F"><gtr:id>41748D4D-016A-42D7-9632-C3261757779F</gtr:id><gtr:name>School of Medicine, Dentistry and Biomedical Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/19D01239-9063-4914-9D02-3D494BE14627"><gtr:id>19D01239-9063-4914-9D02-3D494BE14627</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/617E7220-F6C8-489B-991E-AFD367E83A93"><gtr:id>617E7220-F6C8-489B-991E-AFD367E83A93</gtr:id><gtr:name>Aix-Marseille University</gtr:name><gtr:address><gtr:line1>Aix-Marseille University</gtr:line1><gtr:line2>Pharo</gtr:line2><gtr:line4>Marseille</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4C02B63A-6450-44EE-B38C-5D2C0C38D1E8"><gtr:id>4C02B63A-6450-44EE-B38C-5D2C0C38D1E8</gtr:id><gtr:name>University of Rome II (Tor Vergata)</gtr:name><gtr:address><gtr:line1>via Columbia, 2</gtr:line1><gtr:line4>Roma</gtr:line4><gtr:line5>I-00133</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/98394D9D-F27A-4D51-8500-8A03A6735AF1"><gtr:id>98394D9D-F27A-4D51-8500-8A03A6735AF1</gtr:id><gtr:name>Umea University</gtr:name><gtr:address><gtr:line1>Umea University</gtr:line1><gtr:postCode>SE-901 87</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/86310AD1-A8F3-4449-B724-636306A49715"><gtr:id>86310AD1-A8F3-4449-B724-636306A49715</gtr:id><gtr:name>Catholic University (UCSC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/61D20CC7-787C-455B-936A-3E16D0122205"><gtr:id>61D20CC7-787C-455B-936A-3E16D0122205</gtr:id><gtr:name>Semmelweis University</gtr:name><gtr:address><gtr:line1>Semmelweis University</gtr:line1><gtr:line2>Alkotas u. 44</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0F9EAEAD-5674-4E30-8A06-589629F2C422"><gtr:id>0F9EAEAD-5674-4E30-8A06-589629F2C422</gtr:id><gtr:name>Haukeland University Hospital</gtr:name><gtr:address><gtr:line1>Haukeland University Hospital</gtr:line1><gtr:line2>Jonas Liesvei 65</gtr:line2><gtr:postCode>N-5021</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>Inflammation Infection and Repair</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E594C221-4738-4152-9CFD-57F6EB31C620"><gtr:id>E594C221-4738-4152-9CFD-57F6EB31C620</gtr:id><gtr:name>Fraunhofer Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AAA90310-B621-460B-B530-35ADEE45DB78"><gtr:id>AAA90310-B621-460B-B530-35ADEE45DB78</gtr:id><gtr:name>C.H. Boehringer Sohn AG &amp; Ko. KG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/ACC57BAC-A62B-4F30-9904-D2A0D0DAC429"><gtr:id>ACC57BAC-A62B-4F30-9904-D2A0D0DAC429</gtr:id><gtr:name>Shino-Test Corporation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9E00513E-B552-46CE-A64C-C0A5AB380DB0"><gtr:id>9E00513E-B552-46CE-A64C-C0A5AB380DB0</gtr:id><gtr:name>Jagiellonian University</gtr:name><gtr:address><gtr:line1>Golebia 24</gtr:line1><gtr:line4>Krakow</gtr:line4><gtr:line5>PL-31-007</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Poland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C9E7988F-9A77-4D99-9554-A038C31D4C21"><gtr:id>C9E7988F-9A77-4D99-9554-A038C31D4C21</gtr:id><gtr:name>University of Catania</gtr:name><gtr:address><gtr:line1>Viale A Doria 6</gtr:line1><gtr:line2>I-95125</gtr:line2><gtr:line4>Catania</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78CA1442-F154-40E7-964B-12FE667ADBE0"><gtr:id>78CA1442-F154-40E7-964B-12FE667ADBE0</gtr:id><gtr:name>Hvidovre Hospital</gtr:name><gtr:address><gtr:line1>Hvidovre Hospital</gtr:line1><gtr:line2>Kettegard Alle 30</gtr:line2><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:line4>Ghent</gtr:line4><gtr:line5>B-9000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1A0DAB7-FD0B-415C-A58B-F4CFC655E3FC"><gtr:id>D1A0DAB7-FD0B-415C-A58B-F4CFC655E3FC</gtr:id><gtr:name>Academic Medical Center (AMC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/41748D4D-016A-42D7-9632-C3261757779F"><gtr:id>41748D4D-016A-42D7-9632-C3261757779F</gtr:id><gtr:name>School of Medicine, Dentistry and Biomedical Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/19D01239-9063-4914-9D02-3D494BE14627"><gtr:id>19D01239-9063-4914-9D02-3D494BE14627</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/617E7220-F6C8-489B-991E-AFD367E83A93"><gtr:id>617E7220-F6C8-489B-991E-AFD367E83A93</gtr:id><gtr:name>Aix-Marseille University</gtr:name><gtr:address><gtr:line1>Aix-Marseille University</gtr:line1><gtr:line2>Pharo</gtr:line2><gtr:line4>Marseille</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4C02B63A-6450-44EE-B38C-5D2C0C38D1E8"><gtr:id>4C02B63A-6450-44EE-B38C-5D2C0C38D1E8</gtr:id><gtr:name>University of Rome II (Tor Vergata)</gtr:name><gtr:address><gtr:line1>via Columbia, 2</gtr:line1><gtr:line4>Roma</gtr:line4><gtr:line5>I-00133</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/98394D9D-F27A-4D51-8500-8A03A6735AF1"><gtr:id>98394D9D-F27A-4D51-8500-8A03A6735AF1</gtr:id><gtr:name>Umea University</gtr:name><gtr:address><gtr:line1>Umea University</gtr:line1><gtr:postCode>SE-901 87</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/86310AD1-A8F3-4449-B724-636306A49715"><gtr:id>86310AD1-A8F3-4449-B724-636306A49715</gtr:id><gtr:name>Catholic University (UCSC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/61D20CC7-787C-455B-936A-3E16D0122205"><gtr:id>61D20CC7-787C-455B-936A-3E16D0122205</gtr:id><gtr:name>Semmelweis University</gtr:name><gtr:address><gtr:line1>Semmelweis University</gtr:line1><gtr:line2>Alkotas u. 44</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0F9EAEAD-5674-4E30-8A06-589629F2C422"><gtr:id>0F9EAEAD-5674-4E30-8A06-589629F2C422</gtr:id><gtr:name>Haukeland University Hospital</gtr:name><gtr:address><gtr:line1>Haukeland University Hospital</gtr:line1><gtr:line2>Jonas Liesvei 65</gtr:line2><gtr:postCode>N-5021</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D3D3F76B-F553-4E47-8D35-A564C748B364"><gtr:id>D3D3F76B-F553-4E47-8D35-A564C748B364</gtr:id><gtr:firstName>Donna</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F70A69EA-01B9-4814-8349-4C648033F1CE"><gtr:id>F70A69EA-01B9-4814-8349-4C648033F1CE</gtr:id><gtr:firstName>Diane</gtr:firstName><gtr:surname>Laws</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B498D825-B151-479C-B97C-AE9177CA3F49"><gtr:id>B498D825-B151-479C-B97C-AE9177CA3F49</gtr:id><gtr:firstName>Ratko</gtr:firstName><gtr:surname>Djukanovic</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A087746E-286E-423C-95D0-9E2838993CFF"><gtr:id>A087746E-286E-423C-95D0-9E2838993CFF</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Howarth</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/273EC920-0AAE-4C5D-BDF5-E2BC99694958"><gtr:id>273EC920-0AAE-4C5D-BDF5-E2BC99694958</gtr:id><gtr:firstName>Anoop</gtr:firstName><gtr:surname>Chauhan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AA84A3B9-F8C0-4F10-B715-9772E5D9BF7A"><gtr:id>AA84A3B9-F8C0-4F10-B715-9772E5D9BF7A</gtr:id><gtr:firstName>Ramesh</gtr:firstName><gtr:surname>Kurukulaaratchy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800649"><gtr:id>A778838A-6E3A-4CA2-9DAB-2CAD5C74D49A</gtr:id><gtr:title>Wessex severe asthma cohort</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800649</gtr:grantReference><gtr:abstractText>Asthma is a common and disabling problem for many, particularly those with severe persistent disease that prevents them living a normal life. Standard asthma therapies are insufficient to control symptoms in these individuals and they live in fear of exacerbations that require emergency care and hospitalisation. There is thus an urgent need for the identification of novel therapeutic approaches that improve disease control and prevent disease exacerbation. To enable the more rapid conduct of trials with potential new treatments it is important to have well characterised patients, as it is recognised that severe asthma may arise from a range of causes and not all individuals are likely to benefit in the same way with specific interventions. With this in mind, this proposal will gather patients within the Wessex region with severe asthma, to form a Wessex severe asthma cohort, that can undergo detailed characterisation and be available to potentially take parts in trials of new therapies. This characterisation will involve documenting the impact of the disease on daily symptoms and quality of life, focusing on the presence and severity of nasal and sinus symptoms. Measures will be made of how well the lungs are working through a series of breathing tests. Biological samples, such as sputum, collected by inducing coughing, nasal washings, blood and urine will be collected and used to assess the nature, extent and severity of asthmatic inflammation within the airways and body. It is intended that the cohort would act as a focus for the evaluation of novel treatments that are being developed in the hope that they would lead to improvement in asthma in those with more severe disease. The characterisation would help determine which patients might best be selected for different interventions, dependent upon how these work, to give the best chance of identifying better treatments that can be developed to help improve the quality of life in those with severe asthma.</gtr:abstractText><gtr:technicalSummary>This cohort of patients with persistent and severe asthma specifically responds to a significant unmet clinical need and is not duplicated within National Service Framework strategies or any Topic Specific Clinical Research Networks, as none exist for asthma. This will provide well characterised subjects that facilitate the proof of principle investigation of novel therapies with a sound rationale in this group of patients. The collection and characterisation of these patients reflects a strong partnership between NHS and academic respiratory physicians in Wessex and the close geographic localisation makes possible the potential conduct of sophisticated, mechanistic, translational, pharmacological studies that would not be possible in a widely disseminated cohort and for which Southampton has a proven track record. 
Three hundred patients with asthma who, despite regular maintenance therapy at level 4 or level 5 of the British Thoracic Society asthma management guidelines, remain symptomatic and have unstable disease, in that they have a history of severe exacerbation necessitating a course of oral steroids or an increased in maintenance oral steroid dose, will be recruited. Characterisation, in addition to a detailed history which will include details of smoking habit and medication use, will consist of 1) patient centered questionnaires and diary card recording of upper and lower airway symptoms, to evaluate the impact of the disease on the individual, 2) physiological measures of lung function at home and in the laboratory before and after bronchodilator therapy, to assess lung function in relationship to the norm (predicted values), the natural diurnal variation and the short term pharmacological reversibility of any impairment, 3) biological sample collection to evaluate airway inflammation within the upper and lower airways and to store samples from induced sputum, nasal lavage, peripheral blood (serum and plasma) and urine for subsequent biomarker evaluation, for which separate funding would need to be applied for. Additional assessments include documentation of atopic status, measurement of BMI and measurement of urinary cotinine to verify tobacco smoking history. 
A range of potential mechanistic proof of principle studies on novel therapies that could be undertaken on this cohort of patients with severe asthma are detailed, along with possible industrial collaborators. These focus on modifying the effect or exposure to trigger factors (viruses and bacteria), the underlying abnormal airway inflammation (eosinophilic and neutrophilic) or specific disease processes through molecular targeting.</gtr:technicalSummary><gtr:fund><gtr:end>2014-01-10</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>666711</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Respiratory Therapeutic Capability Cluster</gtr:description><gtr:id>F03C411C-CE9F-445E-9185-02A36A32C847</gtr:id><gtr:impact>Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma.</gtr:impact><gtr:piContribution>Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine, Dentistry and Biomedical Sciences</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Infection and Immunity</gtr:department><gtr:description>Respiratory Therapeutic Capability Cluster</gtr:description><gtr:id>460680B0-A63F-4971-93CE-CDE5F635C4D2</gtr:id><gtr:impact>Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma.</gtr:impact><gtr:piContribution>Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Umea University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>7C162E74-A55C-4AB8-B94D-45FAA0978185</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London (ICL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>U-BIOPRED</gtr:description><gtr:id>0660A1FE-196F-46D8-9BA5-3259B0119F72</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Haukeland University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>C3E4EFF7-A033-435D-9F50-18D8C91B614F</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>9009DD8E-E531-49D6-B2C0-BECD9755F125</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shino-Test Corporation</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>serum periostin as a T2 biomarker in severe asthma</gtr:description><gtr:id>6AF26207-DCB0-4EFD-B072-564C4AE90AE0</gtr:id><gtr:impact>European Respiratory Society poster presentation Munich 2014
Serum periostin in asthma: A potential biomarker for stratification in severe treatment-resistant asthma
H. Rupani, L. Lau, J. Ono, S. Ohta, C. Barber, S. Elliot, T. Brown, R. Kurukulaaratchy, A. Chauhan, K. Izuhara, P. Howarth (Southampton, Portsmouth, United Kingdom; Kanagawa, Saga, Japan)</gtr:impact><gtr:partnerContribution>measurement of serum periostin</gtr:partnerContribution><gtr:piContribution>Wessex Severe asthma cohort serum samples</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>C.H. Boehringer Sohn AG &amp; Ko. KG</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Boehringer Ingelheim</gtr:department><gtr:description>Longitudinal follow up study of Wessex Severe Asthma Cohort</gtr:description><gtr:id>F2859AC9-21C2-4727-8B6D-2F72D7E1FB7C</gtr:id><gtr:impact>None as yet as just started</gtr:impact><gtr:partnerContribution>Boehringer Ingelheim will fund the clinical study and sample collection. Further funding will help support the sample analysis, the details of which have yet to be determined and will be undertaken in partnership.</gtr:partnerContribution><gtr:piContribution>PI led study (Professor Peter Howarth) in collaboration with Boehringer Ingelheim to provide follow up data on those participants of the Wessex Severe Asthma Cohort who had sputum and inflammatory mediator measures as part of their initial assessment, to understand phenotype stability and evaluate the relationship between change in inflammation and change in disease control in severe asthma.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Rome Tor Vergata</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>7F53314D-96C4-4988-BC69-61121CBC3078</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Catania</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>83C769BC-BDD1-4EE5-9871-3DB36F333BDF</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Lung Health</gtr:department><gtr:description>AirProm</gtr:description><gtr:id>F71F3BD7-07A5-477B-84E4-8DB22D1236EE</gtr:id><gtr:impact>None to date just started</gtr:impact><gtr:piContribution>Partner in application to EU FP7 for Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM). Contributing CT thorax scans from well characterised severe asthma patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>59C5A7B3-00F2-41AC-9E15-774D4D1F72D4</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Respiratory Therapeutic Capability Cluster</gtr:description><gtr:id>7AF48D16-ACC1-4E57-AB55-0BEA57502542</gtr:id><gtr:impact>Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma.</gtr:impact><gtr:piContribution>Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bern</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>A0C4DEE7-847D-4885-9A10-97C7B0385979</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jagiellonian University</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:department>The Jagiellonian University Medical College</gtr:department><gtr:description>U-BIOPRED</gtr:description><gtr:id>B1FD67B9-4ECE-4FBB-A815-30743244F5B2</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Manchester</gtr:department><gtr:description>Respiratory Therapeutic Capability Cluster</gtr:description><gtr:id>6DFE0F2F-F5D1-42E4-BC32-FA219B2BC294</gtr:id><gtr:impact>Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma.</gtr:impact><gtr:piContribution>Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research (NIHR)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust</gtr:department><gtr:description>Respiratory Therapeutic Capability Cluster</gtr:description><gtr:id>3642C2CA-D494-4D94-8566-B08D5CAC9B2B</gtr:id><gtr:impact>Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma.</gtr:impact><gtr:piContribution>Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion.</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Semmelweiss University</gtr:collaboratingOrganisation><gtr:country>Hungary, Republic of</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>7EE01375-5089-422A-9029-63146EA3B421</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences Nottingham</gtr:department><gtr:description>Asthma UK Genetics of Severe Asthma (AUGOSA)</gtr:description><gtr:id>4F75004C-AB2D-4578-9E0D-90D9D55EC226</gtr:id><gtr:impact>(1)Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WO; GABRIEL Consortium. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010 Sep 23;363(13):1211-21.</gtr:impact><gtr:piContribution>Contributing DNA from Wessex Severe Asthma Cohort for genome wide screen to define genetics of severe asthma</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>7A0587BD-ABF3-447E-ABF7-41A6671A6B79</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fraunhofer Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>31D4854C-CA76-4C4F-BD37-147EE7A79E66</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Manchester</gtr:department><gtr:description>U-BIOPRED</gtr:description><gtr:id>542803DC-9F3E-4538-9906-A6ECE4018B94</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Centre for Respiratory Medicine</gtr:department><gtr:description>Respiratory Therapeutic Capability Cluster</gtr:description><gtr:id>7EB17733-6C9B-484D-A555-E12413BBDD64</gtr:id><gtr:impact>Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma.</gtr:impact><gtr:piContribution>Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Severe Asthma Research Programme</gtr:department><gtr:description>GWAS and severe asthma</gtr:description><gtr:id>12A0D1F4-1A03-49E0-939C-60CBA389A13F</gtr:id><gtr:impact>not yet</gtr:impact><gtr:partnerContribution>Collaboration has been set up with the US Severe Asthma Research Programme (SARP) and their centre for genetic analysis (Wake Forest University with Professors Eugen Bleecker and Debbie Meyers) to undertake a GWAS analysis similar to that conducted on the SARP population. This would serve as validatory data for SARP and novel data for WSAC. Novartis have funded the GWAS analysis through purchase of all the kits and reagents necessary for this to be undertaken. Payment has thus been in kind. Analysis will be in 2014 and interpretation in 2015.</gtr:partnerContribution><gtr:piContribution>The Wessex Severe Asthma Cohort (WSAC)characterisation included the collection of a sample for DNA analysis. There was no funding for this. Partners have been sought to enable this to happen.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Molecular Medical Sciences Nottingham</gtr:department><gtr:description>U-BIOPRED</gtr:description><gtr:id>8C9C06FC-C6E4-4363-A453-620E26D6D885</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Lung Health</gtr:department><gtr:description>Respiratory Therapeutic Capability Cluster</gtr:description><gtr:id>B3A7EA30-FA89-487B-9C7F-7F779825DCE2</gtr:id><gtr:impact>Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma.</gtr:impact><gtr:piContribution>Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>somalogics anlaysis of induced sputum supernatants</gtr:description><gtr:id>97A16D60-196A-44B0-B6F8-9077EF542A89</gtr:id><gtr:impact>awaited</gtr:impact><gtr:partnerContribution>funding of SOMAscan? assay of the samples by SomaLogic inc USA</gtr:partnerContribution><gtr:piContribution>supply of induced sputum supernatants and matching serum samples from Wessex Severe Asthma Cohort</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hvidovre Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>9B61288F-2EE3-4AF0-A780-F13B753E3AF3</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GWAS and severe asthma</gtr:description><gtr:id>3F07EB17-9CD2-4C62-B2E0-8E0DD3425860</gtr:id><gtr:impact>not yet</gtr:impact><gtr:partnerContribution>Collaboration has been set up with the US Severe Asthma Research Programme (SARP) and their centre for genetic analysis (Wake Forest University with Professors Eugen Bleecker and Debbie Meyers) to undertake a GWAS analysis similar to that conducted on the SARP population. This would serve as validatory data for SARP and novel data for WSAC. Novartis have funded the GWAS analysis through purchase of all the kits and reagents necessary for this to be undertaken. Payment has thus been in kind. Analysis will be in 2014 and interpretation in 2015.</gtr:partnerContribution><gtr:piContribution>The Wessex Severe Asthma Cohort (WSAC)characterisation included the collection of a sample for DNA analysis. There was no funding for this. Partners have been sought to enable this to happen.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center (AMC)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>53ECE3D1-63CD-4E99-9317-F6B75A86114F</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Catholic University (UCSC)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>095672A8-AC8F-4D34-8279-8C67681E7EEE</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aix-Marseille University</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>84D4BA53-098F-47F4-B8F3-EEE51E3D5974</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Respiratory Therapeutic Capability Cluster</gtr:description><gtr:id>55130FCD-290C-4E64-9BD6-CBBD682193A1</gtr:id><gtr:impact>Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma.</gtr:impact><gtr:piContribution>Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>U-BIOPRED</gtr:description><gtr:id>330D1C0F-23ED-4117-9BAF-9F58DDCEE125</gtr:id><gtr:impact>IMI severe asthma funding from EU/EFPIA for the consortium of ?23 million

Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ.

An integrative systems biology approach to understanding pulmonary diseases.

Chest. 2010 Jun;137(6):1410-6</gtr:impact><gtr:partnerContribution>Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application</gtr:partnerContribution><gtr:piContribution>The existance of the &amp;quot;Wessex severe asthma cohort&amp;quot; was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>preceptorship severe asthma meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4C452525-8938-42BB-B6DF-27B940AABF9C</gtr:id><gtr:impact>organisation and conduct of a one day workshop on severe asthma for respiratory specialists</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference on Clincal and Pharmacological aspects of asthma management</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ABB72A33-AA75-4AD4-A0F1-EF5FAAFDCEDA</gtr:id><gtr:impact>lecture on &amp;quot;Pharmacological modulation of airway remodelling in asthma&amp;quot; highlighting the preventative strategies in asthma therapy to prevent long term decline in lung function and how this influences everyday practice in asthma management</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Academy of Allergy, Asthma and Clinical Immunology Conference presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0E51AB78-3650-47ED-8581-049C989E5645</gtr:id><gtr:impact>Presentation on &amp;quot;The Airway Microbiome and Asthma&amp;quot; at pleneray symposium on Wednesday 26 June
Presentation entitled &amp;quot;Pathology of the small airways in asthma&amp;quot; at the joint World Allergy Organisation and EAAACI symposium on Monday, 24 June 2013

Involvement in World Allergy Organisation publication on Small Airways and Asthma</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop severe asthma</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E3C96A02-472B-4363-AF2D-425E98F7DBE4</gtr:id><gtr:impact>Workshop considering how to diagnose severe asthma and approaches to severe asthma management, complemented by clinical cases and group discussions</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Allergy Organisation conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CA572FE7-AFBC-41C4-8010-6A94BABBEB02</gtr:id><gtr:impact>Several presentations at International conference relating to aspects of severe asthma. Titles &amp;quot;Asthma therapy based on phenotypes and response to ICS of eosinophilic and non-eosinophilic type&amp;quot;, &amp;quot;Impact of Environmental Factors on Modulating Epithelial Cell Function in Asthma&amp;quot; and &amp;quot;IL-17 and Th17 Cells in Asthma and Inflammation&amp;quot;. These all included data derived from the Wessex Severe Asthma Cohort. Interactions with Korean workers interested in severe asthma.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EU grant review re severe asthma</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C8818100-09AB-4189-B4DA-68B99BFA919E</gtr:id><gtr:impact>IMI JU Interim Review Meeting for U-BIOPRED (project no 115010). Presentation as WP leader.

successful approval of grant progress</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wessex Asthma Network meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>47861196-9B9D-4A85-B98F-C82995D942E4</gtr:id><gtr:impact>presentation on &amp;quot;How can phenotyping guide our management? &amp;quot; to primary care physicians, secondary care specialists, physiotherapists, specialist nurses, specialist commissioners, psychologists and patient representatives. Part of network meeting to promote asthma care and delivery of specialist services within the Wessex Region.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advisory board severe asthma</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>11C3394F-51A9-4E7A-BAF4-9214F2BA4753</gtr:id><gtr:impact>Advisory board concerning drug development in severe asthma</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>talk for Netherlands Lung Foundation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8023F205-EB52-4637-AF08-C0120863A5DE</gtr:id><gtr:impact>talk and workshop for Netherlands Lung Foundation on &amp;quot;Current treatment of asthma and current medical needs&amp;quot; to help in their decision process re forward planning for funding strategy

appreciation of the help given</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Asthma Congress</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7F4E1EC3-5895-4BCE-8A93-660ACBAF701D</gtr:id><gtr:impact>lecture on &amp;quot;Non-Inflammatory mechanisms of airway remodelling&amp;quot; highlighting the importance of addressing bronchoconstriction as well as airway inflammation in management of asthma</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advisory board severe asthma</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6A1E38C4-8059-4E35-A1D9-C8314E9DE60B</gtr:id><gtr:impact>Pharmaceutical company advisory board re drug development in severe asthma

help develop direction of drug development</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newspaper article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CC63D8F3-7869-4260-B16E-DC291BD982D8</gtr:id><gtr:impact>Article in local Southampton Echo newspaper about severe asthma needs and also a second outlining research activity in Southampton

general awareness of asthma</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>894416</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>IMI ENSO-3 award</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:fundingRef>Grant Agreement No 115010</gtr:fundingRef><gtr:id>A4FBA8C2-4954-4EA8-8129-B8DEF46FE9A1</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>479407</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovate Medicines Innitiative/European Union/ European Federation of Pharmaceutical Industries</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>31F8A953-7406-4108-B58D-E6E349329325</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5951787</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stratified Medicine</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M016579/1</gtr:fundingRef><gtr:id>AF83528B-A413-4119-9783-5B4F7235BBB3</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stratified Medicine Pilot projects</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>MRC-NIHR National Phenome Centre</gtr:fundingOrg><gtr:id>1D36922B-2A6A-4E9D-86A1-40C9395A95C1</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1247983</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>12/33 HTA CET Open Call</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:fundingRef>PROJECT: 12/33/28</gtr:fundingRef><gtr:id>60CBAAF1-4AFC-435C-ACB0-E05816D3615A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Multiple targeting of microRNAs as a therapy for asthma 

Scientific Summary: Multiple targeting of microRNAs as a therapy for asthma and Inflammatory Bowel Disease.
The idea is based on the results that we have obtained in our laboratory, where we have observed a dysregulation in the expression of several microRNAs, both in Asthma and Inflammatory Bowel Disease (IBD). We did not stop at this descriptive fact, but studied the implications of this dysregulation, focusing on different microRNAs in different cells types and processes. This approach has facilitated the discovery of synergies or collaborations between multiple microRNAs. We have found that multiple microRNAs may be used simultaneously as therapeutic targets, eliciting a more controlled response that individual microRNAs.
Our initial experiments have shown that microRNAs that have a specific target mRNA (of therapeutic interest) in common tend to increase their affinity for this target when they are simultaneously manipulated in the cell. Having an increased preference for the common therapeutic target, these microRNAs seem to show less avidity for other targets of no therapeutic interest, reducing the potential off target effects of a potential microRNA therapy.
Alveolar macrophages from asthmatics were found to significantly over express a range of miRs, including miR27, miR150, miR152, miR155 and miR375. All of these have seeding sites within the 3'UTRs of genes that lie within host defence pathways which may have a role in asthmatic exacerbation due to rhinoviral infection. MiR-150, miR-152 and miR-375, which were significantly increased in severe asthma (SA), putatively regulate TLR7 expression. Consistent with this we found TLR-7 mRNA and protein (Western blotting) to be significantly reduced in AM from volunteers with SA compared to HC (p&amp;lt;0.003). This was identified as functionally relevant, as AM from SA exhibited deficient interferon-beta (IFN-?? responses to stimulation with both Imiquimod (TLR7 agonist) and HRV16 in comparison to those from HC (each p&amp;lt;0.05). Importantly we were able to reverse this defect using an anti-microRNA oligonucleotide mix that blocked miR-150, miR-152 and miR-375, indicative of the relevance of these miRs. This innate recognition defect will be compounded, as MiR-27, miR-152 and miR155 are predicted to target Ripk1 (which inhibits TNF-a secretion). Consistent with this we found that transfection with a mix of oligonucleotide mimics for these 3 miRs enhanced the gene expression of TNF-a in alveolar macrophages after their exposure to HRV16. Additional results also suggest the relevance of miRs to altered AM bacterial recognition in asthma.
In epithelial cells from asthmatics we have found that several microRNAs are significantly downregulated (miR-18, miR19, miR-27a, miR-128 and miR-155). All of these microRNAs target the TGF-b pathway in epithelium (targeting SMAD2 and the receptor for TGF-b), an important pro-remodelling factor thought to be key in asthma pathogenesis. MicroRNA reduction in asthmatic epithelial cells increases their sensitivity to asthma, favouring expression of pro-fibrotic genes and facilitating rhinoviral replication. 
In samples from patients suffering of IBD we found that miR-31 and miR-155 were upregulated and that both microRNAs target IL13RA1, the mRNA for the receptor of IL13, a key cytokine in IBD. By using both pre-miR-31 and pre-miR-155 oligonucleotides simultaneously on clinical biopsies from inflamed colon, we were able to show that genes dependent on IL13 stimulation were reduced (CCL18, SOCS1). Importantly, using the pre-miR-155 oligonucleotide alone increased TNF-?, an undesired and dangerous off target effect. However, when miR-155 was combined with pre-miR-31 this effect disappeared and only the common effects (reduction of IL13 dependent genes) were apparent and further increased.
We claim that, by using multiple microRNA therapy, specific to pathology related signalling pathways and to the affected cells (epithelium, macrophages, etc) we enhance the effect of a potential microRNA therapy an can reduce its off target effect.</gtr:description><gtr:id>E53240E1-A1C4-4E59-924D-1E33205B30A8</gtr:id><gtr:impact>Work on going</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>United Kingdom Patent Application No: 1316651.7, Patent Application No. 14/490 280 in USA</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>University of Southampton for MicroRNA Treatment for Asthma (11413 / BB Ref. JDM68318P.USP)</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>local asthma guidelines</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>86660AEC-7E24-4A56-8CC3-B5DB2CC22F09</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NHS Severe Asthma Commissioning</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>26F5AE04-6591-4669-9024-B39A66DE90AF</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/06363DE7-C857-42FA-AA33-6A32354899AF"><gtr:id>06363DE7-C857-42FA-AA33-6A32354899AF</gtr:id><gtr:title>CaMKII is essential for the proasthmatic effects of oxidation.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72a65512d5a2598f4d6152170ee465bc"><gtr:id>72a65512d5a2598f4d6152170ee465bc</gtr:id><gtr:otherNames>Sanders PN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1A22749-E780-438E-A3E2-5F8C80BFCA81"><gtr:id>B1A22749-E780-438E-A3E2-5F8C80BFCA81</gtr:id><gtr:title>Evaluation of a rapid lateral flow immunoassay for Staphylococcus aureus detection in respiratory samples.</gtr:title><gtr:parentPublicationTitle>Diagnostic microbiology and infectious disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b21b77e12a5454bbf1103f64f2f2f304"><gtr:id>b21b77e12a5454bbf1103f64f2f2f304</gtr:id><gtr:otherNames>Wiriyachaiporn S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-8893</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BC9A6642-B2CB-481F-8407-821F4D09DAF2"><gtr:id>BC9A6642-B2CB-481F-8407-821F4D09DAF2</gtr:id><gtr:title>Airway and peripheral urokinase plasminogen activator receptor is elevated in asthma, and identifies a severe, nonatopic subset of patients.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3caae8bb41bad3529bd1a928096e4f76"><gtr:id>3caae8bb41bad3529bd1a928096e4f76</gtr:id><gtr:otherNames>Portelli MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB34FD87-D525-4998-928E-36BAF5D74368"><gtr:id>BB34FD87-D525-4998-928E-36BAF5D74368</gtr:id><gtr:title>Barrier responses of human bronchial epithelial cells to grass pollen exposure.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2b9d2cf18d6caad596bebc041d226187"><gtr:id>2b9d2cf18d6caad596bebc041d226187</gtr:id><gtr:otherNames>Blume C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89A753C5-E905-4CCB-B75E-74E7082CA0C0"><gtr:id>89A753C5-E905-4CCB-B75E-74E7082CA0C0</gtr:id><gtr:title>Mepolizumab treatment in patients with severe eosinophilic asthma.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e15b1e23102f4e7f4392380a3ea449f"><gtr:id>8e15b1e23102f4e7f4392380a3ea449f</gtr:id><gtr:otherNames>Ortega HG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16637245-A8C7-4140-9064-A88EB6B39AD7"><gtr:id>16637245-A8C7-4140-9064-A88EB6B39AD7</gtr:id><gtr:title>A large-scale, consortium-based genomewide association study of asthma.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d580487fad241025575d538bdd124df"><gtr:id>0d580487fad241025575d538bdd124df</gtr:id><gtr:otherNames>Moffatt MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CD068C55-0241-40A4-863F-59A1BA9FF6E1"><gtr:id>CD068C55-0241-40A4-863F-59A1BA9FF6E1</gtr:id><gtr:title>Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/120396197daed2aafc88b77aa88f1912"><gtr:id>120396197daed2aafc88b77aa88f1912</gtr:id><gtr:otherNames>Hinks TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/189E88A4-28C9-45E0-9D27-2C186BDA916F"><gtr:id>189E88A4-28C9-45E0-9D27-2C186BDA916F</gtr:id><gtr:title>CD48 on blood leukocytes and in serum of asthma patients varies with severity.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0fdcb6f72e93dae9c485e5692c1db936"><gtr:id>0fdcb6f72e93dae9c485e5692c1db936</gtr:id><gtr:otherNames>Gangwar RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/12F5AEF0-7649-4EB8-A184-B6B136A950C8"><gtr:id>12F5AEF0-7649-4EB8-A184-B6B136A950C8</gtr:id><gtr:title>Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7a45d701f4ef5ee26a6abcbf67e73393"><gtr:id>7a45d701f4ef5ee26a6abcbf67e73393</gtr:id><gtr:otherNames>Hinks T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D73F0CAB-78DA-4634-A34B-8997BD4AE85E"><gtr:id>D73F0CAB-78DA-4634-A34B-8997BD4AE85E</gtr:id><gtr:title>Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/196260af99aec105dadcc0b8ace298d9"><gtr:id>196260af99aec105dadcc0b8ace298d9</gtr:id><gtr:otherNames>Pavord ID</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8308124D-F70A-45F2-8D42-3A95CC5EA518"><gtr:id>8308124D-F70A-45F2-8D42-3A95CC5EA518</gtr:id><gtr:title>Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanisms.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/120396197daed2aafc88b77aa88f1912"><gtr:id>120396197daed2aafc88b77aa88f1912</gtr:id><gtr:otherNames>Hinks TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6832D9B-0514-4D9C-8F52-8490F75AD620"><gtr:id>E6832D9B-0514-4D9C-8F52-8490F75AD620</gtr:id><gtr:title>Toll-like Receptor 7 Is Reduced in Severe Asthma and Linked to an Altered MicroRNA Profile.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a293a2f83814805fb9e3fd25a429d6d"><gtr:id>2a293a2f83814805fb9e3fd25a429d6d</gtr:id><gtr:otherNames>Rupani H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11A1F39B-F56E-45DF-804D-A268685083EB"><gtr:id>11A1F39B-F56E-45DF-804D-A268685083EB</gtr:id><gtr:title>TNF-a-mediated bronchial barrier disruption and regulation by src-family kinase activation.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b69b12188dfea44a3cda6a72e268d1e"><gtr:id>9b69b12188dfea44a3cda6a72e268d1e</gtr:id><gtr:otherNames>Hardyman MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/20D58EF1-01A5-4553-A249-0F6B3D729D4D"><gtr:id>20D58EF1-01A5-4553-A249-0F6B3D729D4D</gtr:id><gtr:title>Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d0cc29fc53494802d4a0756035b6767"><gtr:id>4d0cc29fc53494802d4a0756035b6767</gtr:id><gtr:otherNames>Bel EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96A2A96B-88F8-47F7-9FD2-F1F537BE1C8F"><gtr:id>96A2A96B-88F8-47F7-9FD2-F1F537BE1C8F</gtr:id><gtr:title>Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/822aefb65f696d3be2c1addf7ade0f22"><gtr:id>822aefb65f696d3be2c1addf7ade0f22</gtr:id><gtr:otherNames>Nair P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/434474A5-C4B3-418E-BC28-ECD70BCB080E"><gtr:id>434474A5-C4B3-418E-BC28-ECD70BCB080E</gtr:id><gtr:title>Asthmatic and normal respiratory epithelial cells respond differently to mechanical apical stress.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26e8166ed388165d7a3225ca24890017"><gtr:id>26e8166ed388165d7a3225ca24890017</gtr:id><gtr:otherNames>Grainge C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/324B8574-C61E-4F80-A2DB-E67354F7A2CE"><gtr:id>324B8574-C61E-4F80-A2DB-E67354F7A2CE</gtr:id><gtr:title>Airway Surfactant Protein D Deficiency in&amp;nbsp;Adults With Severe Asthma.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9816904a61f2484a4c84c02c6f583689"><gtr:id>9816904a61f2484a4c84c02c6f583689</gtr:id><gtr:otherNames>Mackay RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74E8608A-2146-4CE5-B6A2-D869B1DB87BA"><gtr:id>74E8608A-2146-4CE5-B6A2-D869B1DB87BA</gtr:id><gtr:title>Altered Epithelial Gene Expression in Peripheral Airways of Severe Asthma.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8fac5a1f8cc08d60fcad4a7867269b3"><gtr:id>c8fac5a1f8cc08d60fcad4a7867269b3</gtr:id><gtr:otherNames>Singhania A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D6BC59D5-D6DF-4EAA-8A53-F13D3C8E5E2D"><gtr:id>D6BC59D5-D6DF-4EAA-8A53-F13D3C8E5E2D</gtr:id><gtr:title>Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f4ffde7d1677ffe2c4313033fb3809be"><gtr:id>f4ffde7d1677ffe2c4313033fb3809be</gtr:id><gtr:otherNames>Bachert C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/06E4CF9F-C947-468D-BC17-E4B548E0F523"><gtr:id>06E4CF9F-C947-468D-BC17-E4B548E0F523</gtr:id><gtr:title>A microRNA network dysregulated in asthma controls IL-6 production in bronchial epithelial cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/454bfcc6b86e69fa0e13f05b526dd3e9"><gtr:id>454bfcc6b86e69fa0e13f05b526dd3e9</gtr:id><gtr:otherNames>Martinez-Nunez RT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2DF2843C-6369-4B2F-8651-4EFECF47553A"><gtr:id>2DF2843C-6369-4B2F-8651-4EFECF47553A</gtr:id><gtr:title>Response.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9816904a61f2484a4c84c02c6f583689"><gtr:id>9816904a61f2484a4c84c02c6f583689</gtr:id><gtr:otherNames>Mackay RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/235F149D-1911-4252-8867-01CB0CEF435D"><gtr:id>235F149D-1911-4252-8867-01CB0CEF435D</gtr:id><gtr:title>Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12df2ac4e1f46f87465e17ed18f05e7c"><gtr:id>12df2ac4e1f46f87465e17ed18f05e7c</gtr:id><gtr:otherNames>Green BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C1BA2A78-8A25-4BF3-AC30-EFF6EB1A5DF6"><gtr:id>C1BA2A78-8A25-4BF3-AC30-EFF6EB1A5DF6</gtr:id><gtr:title>Case series reporting the effectiveness of mycophenolate mofetil in treatment-resistant asthma.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26e8166ed388165d7a3225ca24890017"><gtr:id>26e8166ed388165d7a3225ca24890017</gtr:id><gtr:otherNames>Grainge C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB748713-E500-4C1B-B2C6-D0C37DEA8EBD"><gtr:id>DB748713-E500-4C1B-B2C6-D0C37DEA8EBD</gtr:id><gtr:title>Genome-wide association study to identify genetic determinants of severe asthma.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1f26c10106673320fbbc68b81aace55c"><gtr:id>1f26c10106673320fbbc68b81aace55c</gtr:id><gtr:otherNames>Wan YI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800649</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>